ArticleJournal of medical case reports2025
Dowling-Degos disease in a 23-year-old Jordanian male: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDowling-Degos disease is a rare genodermatosis disorder that presents as an autosomal dominant trait during late childhood or in adolescence and is also known as reticulate pigmented anomaly of flexures, Dowling-Degos-Kitamura, or dark dot disease. Dowling-Degos disease is characterized by acquired reticular hyperpigmentation, and manifests as a clustered or reticulated pattern mainly at flexural sites, especially in the folds of the skin with comedone-like follicular papules and pitted perioral scars. It appears in both genders but is more likely in females. CASE PRESENTATION: A 23-year-old Jordanian male presented with progressive hyperpigmented macules and papules on his forehead, initially managed with Triderma cream without improvement. Histopathological examination via punch biopsies revealed features consistent with Dowling-Degos disease, excluding malignancy. Treatment was transitioned to sunblock, depigmenting agents (Isis Unit One 4 White), and moisturizers, resulting in significant fading of lesions after 8 months. Genetic counseling was provided owing to the hereditary nature of Dowling-Degos disease, and long-term management strategies were emphasized.
conclusionDowling-Degos disease is a rare genodermatosis that can cause significant psychological distress and a decline in quality of life. Despite challenging treatment, a multidisciplinary approach is essential for improving patient outcomes and managing the elevated risk of skin cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.